Clinical Trial Update: Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating zoledronic acid (Zometa) as adjuvant treatment for malignant pleural effusion due to non-small cell lung cancer was terminated, with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Effusion
• Non-small Cell Lung Cancer

Drugs mentioned

• Zometa (Zoledronic acid)

Snippet

Sponsor: Peter Bushunow MD | Conditions: Malignant Pleural Effusion, Non Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2012-12-04